Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Scleroderma Pulmonary Interstitial Fibrosis
NCT00764309Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2009
- Primary completion
- Jun 2010
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), sponsored by Bristol Myers Squibb. Started Jan 2009; status: completed.
02
Drugs
dasatinib
03
Conditions
Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Beyond the preview
Go deeper on NCT00764309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00764309.